Stadlbauer, Daniel http://orcid.org/0000-0001-6792-7650
McMahon, Meagan http://orcid.org/0000-0002-7450-6624
Turner, Hannah L.
Zhu, Xueyong http://orcid.org/0000-0002-6021-3740
Wan, Hongquan http://orcid.org/0000-0002-6374-0343
Carreño, Juan Manuel
O’Dell, George
Strohmeier, Shirin
Khalil, Zain
Luksza, Marta
van Bakel, Harm http://orcid.org/0000-0002-1376-6916
Simon, Viviana http://orcid.org/0000-0002-6416-5096
Ellebedy, Ali H. http://orcid.org/0000-0002-6129-2532
Wilson, Ian A. http://orcid.org/0000-0002-6469-2419
Ward, Andrew B. http://orcid.org/0000-0001-7153-3769
Krammer, Florian http://orcid.org/0000-0003-4121-776X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400008C, 75N93019C00051)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 26 June 2021
Accepted: 12 December 2022
First Online: 21 December 2022
Competing interests
: Washington University has filed a patent application for antibodies 1G01, 1E01, and 1G04 with A.H.E., F.K., and I.A.W. named as inventors and A.H.E., F.K., and I.A.W. have received royalties from licensing 1G01 for clinical development. F.K. is currently consulting for Avimex, GSK, Third Rock Ventures, and Pfizer and is receiving research support from Dynavax. Research support was provided in the past by GSK and Pfizer to the Krammer laboratory. The Ellebedy laboratory received funding from Emergent BioSolutions, Moderna, and AbbVie in the form of scientific research agreements that are unrelated to the data presented in the current study. The remaining authors declare no competing interests.